carbostyril has been researched along with Lupus Erythematosus, Systemic in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sanz, I | 1 |
Parikh, SV; Rovin, BH | 1 |
Hahn, BH; Lourenço, EV; Palma-Diaz, MF; Skaggs, BJ; Wong, M | 1 |
Furie, R; Narain, S | 1 |
Alsina, M; Bennàssar, A; Guilabert, A; Mascaró, JM; Pintor, L | 1 |
Bang, L; Harris, TB; Mian, A; Muscal, E | 1 |
Attademo, L; Moretti, P; Quartesan, R | 1 |
Bokarewa, M; Carlsten, H; Jonsson, C; Svensson, L; Tarkowski, A | 1 |
2 review(s) available for carbostyril and Lupus Erythematosus, Systemic
Article | Year |
---|---|
Lupus nephritis: the evolving role of novel therapeutics.
Topics: Abatacept; Acute Kidney Injury; Adolescent; Algorithms; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Apoptosis; Autoantibodies; B-Lymphocytes; Cytokine TWEAK; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Humans; Immunoconjugates; Immunosuppressive Agents; Interleukin-6; Lupus Erythematosus, Systemic; Lupus Nephritis; Quinolones; Remission Induction; Rituximab; Tumor Necrosis Factor Inhibitors | 2014 |
Update on clinical trials in systemic lupus erythematosus.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Clinical Trials as Topic; Cyclosporine; Herpes Zoster; Humans; Immunosuppressive Agents; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Maintenance Chemotherapy; Peptide Fragments; Plasma Cells; Quinolones; Recombinant Fusion Proteins; Remission Induction; T-Lymphocytes; Tacrolimus; Treatment Outcome | 2016 |
6 other study(ies) available for carbostyril and Lupus Erythematosus, Systemic
Article | Year |
---|---|
New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.
Topics: Antibodies, Monoclonal, Humanized; Biomedical Research; Calcineurin Inhibitors; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Cytokines; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Inflammasomes; Lupus Erythematosus, Systemic; Lymphocyte Depletion; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Quinolones; Rheumatology | 2017 |
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Topics: Animals; Disease Models, Animal; Interferon-gamma; Interleukin-10; Interleukin-17; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphocytes; Mice; Myeloid Cells; Quinolones; Tumor Necrosis Factor-alpha | 2014 |
Treatment of delusional parasitosis with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; HIV Infections; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Piperazines; Quinolones; Skin Diseases, Parasitic | 2009 |
Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
Topics: Adolescent; Adrenal Cortex Hormones; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Remission Induction; Treatment Outcome; Weight Gain | 2011 |
[Efficacy of aripiprazole on cognitive and behavioral changes in a young woman with systemic lupus erythematosus].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Lupus Erythematosus, Systemic; Mental Disorders; Piperazines; Quinolones | 2012 |
The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus.
Topics: Animals; Disease Models, Animal; Female; Immunity, Innate; Immunoglobulins; Immunologic Factors; Lupus Erythematosus, Systemic; Lymphocyte Activation; Male; Mice; Mice, Inbred MRL lpr; Quinolones; T-Lymphocytes; Transcription Factors | 2004 |